Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129722 | 1.00 | CYP2C9 (0.55) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL11524101 | 0.95 | CYP3A4 (0.60) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL3620867 | 0.95 | CYP3A4 (0.60) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL6635785 | 0.95 | CYP3A4 (0.60) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL1878786 | 0.94 | CYP3A4 (0.57) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL10346503 | 0.92 | CYP3A4 (0.58) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL12416611 | 0.92 | CYP3A4 (0.58) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL5665735 | 0.89 | CYP3A4 (0.54) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL5665730 | 0.89 | CYP3A4 (0.54) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B | |
| SCHEMBL12416633 | 0.88 | CYP3A4 (0.62) | CYP2C9CYP3A4CYP2D6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158135-B2 | Imine based liquid crystals for the controlled release of bioactive materials | FIRMENICH SA (CH) | 2012-04-17 | — | — | US | disclosed |
| EP-2010231-B1 | IMINE BASED LIQUID CRYSTALS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS | FIRMENICH & CIE (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20090306196-A1 | IMINE BASED LIQUID CRYSTALS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS | FIRMENICH SA (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-2010231-A2 | IMINE BASED LIQUID CRYSTALS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS | Firmenich S.A. (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007113711-A2 | IMINE BASED LIQUID CRYSTALS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS | FIRMENICH SA (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306196-A1 | IMINE BASED LIQUID CRYSTALS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS | BCHE, ACHE, LIPE | CYP2C9 345/4885CYP3A4 1225/4885CYP2D6 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.